A recent multicentre placebo-controlled trial by Rolnick et al. has indicated that taking 150 mg aspirin daily in women at high risk of pre-eclampsia reduced the incidence of the disease from 4.3% to 1.5% in comparison with placebo. Although the findings of this study are important, a high proportion of women withdrew their consent and not all safety outcomes have been reported. This journal watch article discusses the paper in more detail.
RolnikDLWrightDPoonLCet al.
Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med2017;
377: 613–622.
2.
PoonLCWrightDRolnikDLet al.
Aspirin for evidence-based preeclampsia prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history. Am J Obstet Gynecol2017;
217: 585.e1–585.e5.
3.
AskieLMDuleyLHenderson-SmartDJet al.
Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet2007;
369: 1791–1798.
4.
BujoldERobergeSLacasseYet al.
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol2010;
116: 402–414.
5.
RobergeSNicolaidesKHDemersSet al.
Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis. Ultrasound Obstet Gynecol2013;
41: 491–499.
6.
NICE. Hypertension in pregnancy: diagnosis and management.
London:
NICE, 2010.
7.
American College of Obstetricians and Gynecologists and Task Force on Hypertension in Pregnancy.
Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol2013;
122: 1122–1131.
8.
RobergeSNicolaidesKDemersSet al.
The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol2017;
216: 110–120.e6.
